Kabra Drugs Statistics

Total Valuation

Kabra Drugs has a market cap or net worth of INR 611.19 million. The enterprise value is 498.89 million.

Market Cap	611.19M
Enterprise Value	498.89M

Important Dates

The next estimated earnings date is Friday, May 29, 2026.

Earnings Date	May 29, 2026
Ex-Dividend Date	n/a

Share Statistics

Kabra Drugs has 23.71 million shares outstanding. The number of shares has increased by 144.81% in one year.

Current Share Class	23.71M
Shares Outstanding	23.71M
Shares Change (YoY)	+144.81%
Shares Change (QoQ)	-0.38%
Owned by Insiders (%)	22.52%
Owned by Institutions (%)	0.24%
Float	18.37M

Valuation Ratios

The trailing PE ratio is 12.68.

PE Ratio	12.68
Forward PE	n/a
PS Ratio	1.07
PB Ratio	2.35
P/TBV Ratio	2.35
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	11.61
EV / Sales	0.87
EV / EBITDA	13.51
EV / EBIT	13.55
EV / FCF	n/a

Financial Position

Current Ratio	n/a
Quick Ratio	n/a
Debt / Equity	0.02
Debt / EBITDA	0.13
Debt / FCF	n/a
Interest Coverage	1,472.64

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	22.80%
Return on Capital Employed (ROCE)	n/a
Weighted Average Cost of Capital (WACC)	2.29%
Revenue Per Employee	18.49M
Profits Per Employee	1.39M
Employee Count	31
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Kabra Drugs has paid 4.02 million in taxes.

Income Tax	4.02M
Effective Tax Rate	8.56%

Stock Price Statistics

The stock price has increased by +132.67% in the last 52 weeks. The beta is -0.35, so Kabra Drugs's price volatility has been lower than the market average.

Beta (5Y)	-0.35
52-Week Price Change	+132.67%
50-Day Moving Average	29.71
200-Day Moving Average	23.26
Relative Strength Index (RSI)	31.75
Average Volume (20 Days)	87,004

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Kabra Drugs had revenue of INR 573.34 million and earned 42.96 million in profits. Earnings per share was 2.03.

Revenue	573.34M
Gross Profit	67.36M
Operating Income	36.82M
Pretax Income	46.99M
Net Income	42.96M
EBITDA	36.93M
EBIT	36.82M
Earnings Per Share (EPS)	2.03

Full Income Statement

Balance Sheet

The company has 116.99 million in cash and 4.69 million in debt, with a net cash position of 112.29 million or 4.74 per share.

Cash & Cash Equivalents	116.99M
Total Debt	4.69M
Net Cash	112.29M
Net Cash Per Share	4.74
Equity (Book Value)	259.92M
Book Value Per Share	10.90
Working Capital	n/a

Full Balance Sheet

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Depreciation & Amortization	109,750
Net Borrowing	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 11.75%, with operating and profit margins of 6.42% and 7.49%.

Gross Margin	11.75%
Operating Margin	6.42%
Pretax Margin	8.19%
Profit Margin	7.49%
EBITDA Margin	6.44%
EBIT Margin	6.42%
FCF Margin	n/a

Dividends & Yields

Kabra Drugs does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-144.81%
Shareholder Yield	-144.81%
Earnings Yield	7.03%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1